These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 11978156)

  • 21. [Lansoprazole versus ranitidine in the prevention of early recurrences of digestive hemorrhages from gastroduodenal ulcers. Randomized double-blind multicenter study].
    Michel P; Duhamel C; Bazin B; Raoul JL; Person B; Bigard MA; Legoux JL; Sallerin V; Colin R
    Gastroenterol Clin Biol; 1994; 18(12):1102-5. PubMed ID: 7750682
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Collagenous colitis associated with lansoprazole.
    Wilcox GM; Mattia A
    J Clin Gastroenterol; 2002 Feb; 34(2):164-6. PubMed ID: 11782613
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications.
    Lai KC; Chu KM; Hui WM; Wong BC; Hu WH; Wong WM; Chan AO; Wong J; Lam SK
    Am J Med; 2005 Nov; 118(11):1271-8. PubMed ID: 16271912
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of patients with Zollinger-Ellison syndrome.
    Mignon M; Pospai D; Forestier S; Vatier J; Vallot T
    Clin Ther; 1993; 15 Suppl B():22-31. PubMed ID: 8205592
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An extensive metabolizer with recurrent ulcer responding to high dose of lansoprazole.
    Higuchi K; Tanabe S; Koizumi W; Nakayama N; Sasaki T; Nagaba S; Saigenji K; Katada N
    Hepatogastroenterology; 2004; 51(57):774-6. PubMed ID: 15143914
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lansoprazole: a cause of secretory diarrhea.
    Goff JS
    Am J Gastroenterol; 1998 Nov; 93(11):2298-9. PubMed ID: 9820425
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Proton pump inhibitor for ulcer therapy. Tolerance profile of lansoprazole].
    Müller P; Fuchs W; Peifer-Weiss A; Simon B
    Fortschr Med; 1998 Oct; 116(28):31-2. PubMed ID: 9844264
    [No Abstract]   [Full Text] [Related]  

  • 28. Fatal toxic epidermal necrolysis due to lansoprazole.
    Heaton NR; Edmonds EV; Francis ND; Bunker CB; Bowling JC; Morar N
    Clin Exp Dermatol; 2004 Nov; 29(6):612-3. PubMed ID: 15550134
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bismuth subsalicylate instead of metronidazole with lansoprazole and clarithromycin for Helicobacter pylori infection: a randomized trial.
    Chey WD; Fisher L; Elta GH; Barnett JL; Nostrant T; DelValle J; Hasler WL; Scheiman JM
    Am J Gastroenterol; 1997 Sep; 92(9):1483-6. PubMed ID: 9317068
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Lansoprazole--a new acid pump inhibitor].
    Ejlersen E; Tage-Jensen U
    Ugeskr Laeger; 1995 May; 157(20):2871-3. PubMed ID: 7785109
    [No Abstract]   [Full Text] [Related]  

  • 31. [Gynecomastia associated with the simultaneous use of cisapride and lansoprazole].
    Cuervo Martín JR; García Ortega P; Sánchez Sánchez A; Carvajal García-Pando A
    Med Clin (Barc); 2001 Mar; 116(11):437-8. PubMed ID: 11333695
    [No Abstract]   [Full Text] [Related]  

  • 32. Safety of omeprazole and lansoprazole.
    Colin-Jones D
    Lancet; 1994 May; 343(8909):1369. PubMed ID: 7910362
    [No Abstract]   [Full Text] [Related]  

  • 33. Clinical effectiveness of lansoprazole in patients with gastric ulcers: evaluation of quality of ulcer healing based on endoscopic ultrasonographic findings.
    Obara K; Kuwana T; Ishihata R; Kondo Y; Ejiri Y; Yokogi K; Okubo Y; Ajima H; Mukai S; Kasukawa R
    J Clin Gastroenterol; 1995; 20 Suppl 2():S36-9. PubMed ID: 7594336
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Omeprazole and lansoprazole suspensions for nasogastric administration.
    McAndrews KL; Eastham JH
    Am J Health Syst Pharm; 1999 Jan; 56(1):81. PubMed ID: 10048885
    [No Abstract]   [Full Text] [Related]  

  • 35. Lansoprazole regimens that sustain intragastric pH > 6.0: an evaluation of intermittent oral and continuous intravenous infusion dosages.
    Metz DC; Amer F; Hunt B; Vakily M; Kukulka MJ; Samra N
    Aliment Pharmacol Ther; 2006 Apr; 23(7):985-95. PubMed ID: 16573801
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diarrhea associated with lansoprazole.
    Mukherjee S
    J Gastroenterol Hepatol; 2003 May; 18(5):602-3. PubMed ID: 12702056
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lansoprazole in the treatment of functional dyspepsia: two double-blind, randomized, placebo-controlled trials.
    Peura DA; Kovacs TO; Metz DC; Siepman N; Pilmer BL; Talley NJ
    Am J Med; 2004 Jun; 116(11):740-8. PubMed ID: 15144910
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Dose-response effect of lansoprazole in patients with Zollinger-Ellison syndrome].
    Mignon M; Hochlaf S; Forestier S; Ruszniewski P; Vatier J; Joubert-Collin M
    Gastroenterol Clin Biol; 1994; 18(1):13-6. PubMed ID: 8187984
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Eradication of H. pylori in a developing country: comparison of lansoprazole versus omeprazole with norfloxacin, in a dual-therapy study.
    Gupta VK; Dhar A; Srinivasan S; Rattan A; Sharma MP
    Am J Gastroenterol; 1997 Jul; 92(7):1140-2. PubMed ID: 9219786
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A placebo-controlled dose-ranging study of lansoprazole in the management of reflux esophagitis.
    Earnest DL; Dorsch E; Jones J; Jennings DE; Greski-Rose PA
    Am J Gastroenterol; 1998 Feb; 93(2):238-43. PubMed ID: 9468251
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.